CJC-1295 No DAC 5mg + Ipamorelin 5mg

For research use only. Not for human or animal consumption.

CJC-1295 No DAC + Ipamorelin – 10mg Research Blend

CJC-1295 No DAC + Ipamorelin is a dual-peptide research blend designed for laboratory investigation into growth hormone signalling pathways, recovery mechanisms, and metabolic regulation.

This formulation combines:

• 5mg CJC-1295 No DAC (MOD GRF 1-29)
• 5mg Ipamorelin

Both peptides are widely studied in preclinical environments due to their complementary interaction with endogenous growth hormone release pathways.

CJC-1295 No DAC acts as a modified Growth Hormone Releasing Hormone (GHRH) analogue, while Ipamorelin functions as a selective Growth Hormone Secretagogue Receptor (GHSR) agonist. Together, they are commonly researched for their synergistic signalling properties and controlled pulsatile GH release patterns.

Product Highlights

• Dual peptide blend containing 5mg + 5mg
• Research-focused GH signalling support
• Frequently studied in recovery and metabolic models
• High purity lyophilised peptide formulation
• Batch-tested with analytical verification
• Designed for controlled laboratory research applications

Research Overview

In experimental settings, CJC-1295 No DAC + Ipamorelin is commonly investigated for its role in:

• Growth hormone signalling dynamics
• Peptide-mediated receptor interactions
• Recovery and regeneration models
• Sleep and recovery pathway research
• Metabolic and fat oxidation studies
• Cellular signalling and endocrine response analysis

Researchers value this combination because both compounds stimulate GH release through different mechanisms while maintaining a controlled and balanced response profile.

Mechanism of Action

CJC-1295 No DAC

CJC-1295 No DAC is a shortened GHRH analogue engineered to stimulate natural pulsatile growth hormone release. Unlike DAC-modified versions, it has a shorter half-life, allowing more precise timing and controlled research protocols.

Ipamorelin

Ipamorelin is a selective ghrelin receptor agonist studied for its ability to stimulate GH secretion with minimal interaction with cortisol and prolactin pathways.

Combined Research Interest

The combination is frequently explored in peptide research models investigating:

• GH pulse amplification
• Recovery signalling
• Peptide synergy
• Endocrine pathway modulation
• Controlled peptide-release dynamics

Purity & Quality

Each batch undergoes independent analytical testing to verify:

• Peptide identity
• High purity standards
• Sterility controls
• Batch consistency
• Research-grade quality assurance

COA documentation is available with each batch where applicable.

Storage & Handling

• Supplied as a lyophilised powder
• Store refrigerated at 2–8°C after reconstitution
• Intended for controlled laboratory handling only
• Reconstitute using appropriate laboratory-grade bacteriostatic solution

Package Contents

• 1 × Research vial containing:
  • 5mg CJC-1295 No DAC
  • 5mg Ipamorelin

Total peptide content: 10mg

Important Disclaimer

This product is intended strictly for laboratory and scientific research purposes.

• Not for human consumption
• Not for medical, cosmetic, or veterinary use
• Not intended to diagnose, treat, cure, or prevent disease
• Purchase only if qualified to handle research compounds

Why Researchers Choose This Blend

CJC-1295 No DAC + Ipamorelin remains one of the most researched peptide combinations due to its balanced signalling profile and compatibility with controlled GH pulse studies.

The short-acting nature of both peptides allows researchers to investigate timing-dependent hormone release patterns while maintaining flexible experimental protocols.